IMR Press / FBL / Volume 20 / Issue 2 / DOI: 10.2741/4314

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Protein tyrosine phosphatases in pathological process
Show Less
1 Department of Medical Chemistry, Medical University of Gdansk, Gdansk, Poland
2 Department of Experimental Biomedicine and Clinical Neurosciences, Section of Human Anatomy, University of Palermo, Palermo, Italy
3 Euro-Mediterranean Institute of Science and Technology, Palermo, Italy
Academic Editor:Anna Czarnecka
Front. Biosci. (Landmark Ed) 2015, 20(2), 377–388; https://doi.org/10.2741/4314
Published: 1 January 2015
(This article belongs to the Special Issue Frontiers in molecular medicine)
Abstract

Protein tyrosine phosphatases (PTPs) modulate the cellular level of tyrosine phosphorylation under normal and pathological conditions, and thus exert either stimulatory or inhibitory effect on signal transduction. Hence, PTPs are potential pharmacological targets for novel drugs being developed in order to treat numerous pathologies including cancer. For example, PTPs have been found to play a key role in pathogenesis of autoimmune disorders, allergic response, cardiovascular or neurodegenerative diseases, among others Alzheimer’s disease. Moreover, since many PTPs fine-tune subtle regulation of microbial biochemistry controlling the viability and virulence, they can be candidates for new therapies of infection diseases. In this review, authors summarize the current knowledge on PTPs implication in etiopathogenesis of most common human diseases focusing on PTPs as potential therapeutical targets.

Keywords
Protein tyrosine phosphatases
Tumor supressors
Oncogenes
Virulence effectors
Immune disorders
Review
Share
Back to top